Shares of Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating) have been given a consensus rating of “Hold” by the eight ratings firms that currently cover the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and six have given a hold rating to the company. The average 12-month objective price among analysts that have issued ratings on the stock in the last year is $17.83.

A number of analysts recently commented on ELAN shares. Barclays decreased their price target on Elanco Animal Health from $32.00 to $18.00 and set an “equal weight” rating for the company in a research report on Monday, September 12th. JPMorgan Chase & Co. reduced their price target on Elanco Animal Health from $24.00 to $20.00 and set a “neutral” rating on the stock in a report on Monday, October 17th. The Goldman Sachs Group reduced their price target on Elanco Animal Health from $19.00 to $12.00 and set a “sell” rating on the stock in a report on Wednesday, November 9th. Morgan Stanley cut their objective price on Elanco Animal Health from $21.00 to $20.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 15th. Finally, William Blair reaffirmed a “market perform” rating on shares of Elanco Animal Health in a research report on Tuesday, November 8th.

Elanco Animal Health Trading Down 1.7%

NYSE ELAN opened at $12.21 on Thursday. Elanco Animal Health has a 12 month low of $11.34 and a 12 month high of $31.98. The company has a current ratio of 1.96, a quick ratio of 1.12 and a debt-to-equity ratio of 0.82. The business’s 50-day moving average price is $12.77 and its two-hundred day moving average price is $17.49. The firm has a market capitalization of $5.79 billion, a PE ratio of -50.87, a price-to-earnings-growth ratio of 6.14 and a beta of 0.92.

Insider Buying and Selling at Elanco Animal Health

In other news, Director R David Hoover bought 20,000 shares of the stock in a transaction on Friday, September 9th. The stock was bought at an average cost of $15.18 per share, for a total transaction of $303,600.00. Following the completion of the purchase, the director now directly owns 145,000 shares in the company, valued at $2,201,100. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director R David Hoover bought 20,000 shares of the business’s stock in a transaction dated Friday, September 9th. The stock was acquired at an average price of $15.18 per share, with a total value of $303,600.00. Following the completion of the purchase, the director now directly owns 145,000 shares of the company’s stock, valued at $2,201,100. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Jeffrey N. Simmons bought 30,000 shares of the firm’s stock in a transaction on Friday, September 9th. The stock was purchased at an average price of $14.54 per share, for a total transaction of $436,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 30,000 shares in the company, valued at $436,200. The disclosure for this purchase can be found here. Insiders bought a total of 64,200 shares of company stock worth $938,930 over the last three months. Corporate insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Elanco Animal Health

Several large investors have recently added or reduced their stakes in the business. Herold Advisors Inc. purchased a new stake in shares of Elanco Animal Health in the 1st quarter valued at approximately $26,000. Tcwp LLC acquired a new position in shares of Elanco Animal Health in the 1st quarter valued at $29,000. IndexIQ Advisors LLC acquired a new position in shares of Elanco Animal Health in the 1st quarter valued at $32,000. Northwestern Mutual Wealth Management Co. It boosted its stake in Elanco Animal Health by 147.8% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 1,556 shares of the company’s stock worth $41,000 after purchasing an additional 928 shares during the period. Finally, Steward Partners Investment Advisory LLC boosted its stake in Elanco Animal Health by 165.9% during the 1st quarter. Steward Partners Investment Advisory LLC now owns 1,981 shares of the company’s stock worth $52,000 after purchasing an additional 1,236 shares during the period. 98.15% of the stock is owned by hedge funds and other institutional investors.

About Elanco Animal Health

(Get Rating)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Elanco Animal Health, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Elanco Animal Health wasn’t on the list.

While Elanco Animal Health currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

.